|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colorectal cancer: The epigenetic role of microbiome显示文摘Colorectal cancer(CRC)is the third most common cancer in men(746000 cases per year)and the second most common cancer in women globally(614000 cases per year).The incidence rate of CRC in developed countries(737000 cases per year)is higher than that in less developed countries(624000 cases per year).CRC can arise from genetic causes such as chromosomal instability and microsatellite instability.Several etiologic factors underlie CRC including age,diet,and lifestyle.Gut microbiota represent a proven cause of the disease,where they play pivotal roles in modulating and reshaping the host epigenome.Several active microbial metabolites have been found to drive carcinogenesis,invasion,and metastasis via modifying both the methylation landscape along with histone structure in intestinal cells.Gut microbiota,in response to diet,can exert both beneficial and harmful functions in humans,according to the intestinal balance of number and types of these bacteria.Although the intestinal microbial community is diverse among individuals,these microbes cumulatively produce 100-fold more proteins than the human genome itself,which calls for further studies to elaborate on the complicated interaction between these microorganisms and intestinal cells.Therefore,understanding the exact role that gut microbiota play in inducing CRC will help attain reliable strategies to precisely diagnose and treat this fatal disease. | Hussein Sabit Emre Cevik Huseyin Tombuloglu | 2019 | World Journal of Clinical Cases2019，7，22： | 3 |
| 2 | Cholesterol levels in patients with multiple myeloma显示文摘 | Yavasoglu I Tombuloglu M Kadikoylu G | 2008 | Ann Hematol2008，87，3： | 1 |
| 3 | Fibrinolytic activity and platelet release reaction in essential hypertension显示文摘 | Keskin A Tombuloglu M Buyukkececi F | 1994 | Jpn Heart J1994，35，： | 1 |
| 4 | Transcriptome-wide identification of R2R3-MYB transcription factors in barley with their boron responsive expression analysis显示文摘 | Tombuloglu H Kekec G Sakcali M S | 2013 | Mol Genet Genomics2013，288，34： | 1 |
| 5 | Cholesterol levels in patients with multiple myeloma显示文摘 | Yavasoglu I Tombuloglu M Kadikoylu G | 2008 | Ann Hematol2008，87，3： | 1 |
| 6 | Clinical Side Effects during Peripheral Blood Progenitor Cell Infusion 显示文摘 | Donmez A Tombuloglu M Gungor A | 2007 | Transfus Apher Sci2007，36，1： | 1 |
| 7 | Short-term femoral venous dialysis catheters for autologous peripheral blood progenitor cell collection:Retrospective evaluation in 276 catheter practice from a single center显示文摘 | Donmez A Cagirgan S Tombuloglu M | | 0，，02： | 1 |
| 8 | Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience显示文摘Chronic myeloid leukemia(CML) is a myeloproliferative disease which leads the unregulated growth of myeloid cells in the bone marrow. It is characterized by the presence of Philadelphia chromosome. Reciprocal translocation of the ABL gene from chromosome 9 to 22 t(9; 22)(q34; q11.2) generate a fusion gene(BCRABL). BCR-ABL protein had constitutive tyrosine kinase activity that is a primary cause of chronic phase of CML. Tyrosine kinase inhibitors(TKIs) are now considered standard therapy for patients with CML. Even though, successful treatment with the TKIs, allogeneic stem cell transplantation(ASCT) is still an important option for the treatment of CML, especially for patients who are resistant or intolerant to at least one second generation TKI or for patients with blastic phase. Today, we know that there is no evidence for increased transplantrelated toxicity and negative impact of survival with pretransplant TKIs. However, there are some controversies about timing of ASCT, the optimal conditioning regimens and donor source. Another important issue is that BCRABL signaling is not necessary for survival of CML stem cell and TKIs were not effective on these cells. So, ASCT may play a role to eliminate CML stem cells. In this article, we review the diagnosis, management and treatment of CML. Later, we present our center's outcomes of ASCT for patients with CML and then, we discuss the place of ASCT in CML treatment in the TKIs era. | Nur Soyer Ayse Uysal Murat Tombuloglu Fahri Sahin Guray Saydam Filiz Vural | 2017 | World Journal of Hematology2017，6，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员